Lund adult psychiatric hospital
Lund, Skåne County, 22185, Sweden
Location status: Recruiting
NCT Number: NCT06106555
The objective of this project is to investigate factors that contribute to the success and lack of success in DBT among individuals with BPD and a history of self-harm in a clinical psychiatric setting.
1. Do certain personality factors and identity disturbance predict the treatment outcome of DBT in individuals with BPD? 2. Do changes in identity disturbance, self-hate, or emotion regulation mediate the treatment outcome of DBT in individuals with BPD? 3. Do specific personality profiles moderate the treatment outcomes of DBT for individuals with BPD? 4. When does the primary treatment effect occur, and does this effect persist after a 12-month follow-up period?
Interested in participating?
Request Info18 year and older
All sexes
Observational
Lund, Skåne County, 22185, Sweden
Location status: Recruiting
Borderline Personality Disorder (BPD) is a complex and enduring mental health condition characterized by a range of symptoms. The consequences of BPD are severe, causing individual suffering, impairments in daily functioning, and increased mortality rates. Dialectical behavior therapy (DBT) is one of the most widely used treatment models for BPD and self-harm. DBT has demonstrated positive outcomes but not all individuals benefit equally from this therapy, highlighting the need for further exploration. Specifically, there is a knowledge gap regarding what predicts positive treatment response. Research exploring this topic, has highlighted the potential significance of emotion regulation, personality profiles, self-concept, and identity disturbance in understanding the outcomes of individuals with BPD.
The primary objective of this research project is to investigate the factors that contribute to the success and lack of success in DBT.
All individuals referred to DBT-treatment in the Adult psychiatric clinic in Lund will be offered participation in the study. All study participants receive the same treatment as those who chose not to participate. Measures will commence after treatment contracts have been negotiated and the treatment will continue up to a maximum treatment length of one year.
Data will be retrieved from databases, medical records as well as collected as self-report forms. Self-report measures will be conducted every three months, at end of treatment and at follow up 12 months after end of treatment. Data from registries and charts will be collected at time of consent and at follow up 12 months after treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan
Time frame: Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Indirect and direct self-harm
Time frame: Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Daily functioning and impairment
Time frame: Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Borderline symptoms
Time frame: Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Personality functioning
Time frame: Treatment start, 3,6,9 and at end of treatment and at follow up at 24 months.
Personality structure
Time frame: Treatment at end of treatment and at follow up at 24 months.
Days admitted to a psychiatric ward past year
Contact information is provided by the study sponsor or research team.
Region Skane
Other
Vilka Faktorer påverkar Behandlingsutfall Vid Dialektisk Beteendeterapi för Borderline Personlighetssyndrom?
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06424509
Behavior, Behavioral Symptoms
Lund, Sweden
View Trial DetailsNCT02988037
Behavior, Behavioral Symptoms
View Trial DetailsNCT04318899
Behavior, Behavioral Symptoms
Oslo, Norway
View Trial DetailsNCT03846375
Behavior, Behavioral Symptoms
Bergen, Norway
View Trial Details